These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6537893)

  • 1. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity.
    Salem P; Khalyl M; Jabboury K; Hashimi L
    Cancer; 1984 Feb; 53(4):837-40. PubMed ID: 6537893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.
    Forastiere AA; Belliveau JF; Goren MP; Vogel WC; Posner MR; O'Leary GP
    Cancer Res; 1988 Jul; 48(13):3869-74. PubMed ID: 3378222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion.
    Salem P; Hall SW; Benjamin RS; Murphy WK; Wharton JT; Bodey GP
    Cancer Treat Rep; 1978 Oct; 62(10):1553-5. PubMed ID: 361227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
    Lokich JJ
    Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-hour infusion of cis-platinum in head and neck cancers.
    Jacobs C; Bertino JR; Goffinet DR; Fee WE; Goode RL
    Cancer; 1978 Nov; 42(5):2135-40. PubMed ID: 719601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of two administration schedules of cis-dichlorodiammineplatinum (DDP) in ovarian and head and neck cancers: a CMEA chemotherapy group study.
    Mechl Z; Kerpel-Fronius S; Decker A; Gorbunova VA; Gürtler R; Hindy I; Krafft W; Kolarić K; Nekulova M; Sopkova B
    Neoplasma; 1987; 34(1):37-43. PubMed ID: 3561604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cis-diamminedichloroplatinum (II). A new anticancer drug.
    Rozencweig M; von Hoff DD; Slavik M; Muggia FM
    Ann Intern Med; 1977 Jun; 86(6):803-12. PubMed ID: 326117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.
    Stewart DJ; Wallace S; Feun L; Leavens M; Young SE; Handel S; Mavligit G; Benjamin RS
    Cancer Res; 1982 May; 42(5):2059-62. PubMed ID: 7199971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum.
    Sako K; Razack MS; Kalnins I
    Am J Surg; 1978 Oct; 136(4):529-33. PubMed ID: 707737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of prolonged intravenous infusions of cisplatin in patients with malignant neoplasms].
    Tiuliadin SA
    Vopr Onkol; 1983; 29(12):40-4. PubMed ID: 6582683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of fractionated low and single high dose cisplatin in various tumors.
    Schilcher RB; Wessels M; Niederle N; Seeber S; Schmidt CG
    J Cancer Res Clin Oncol; 1984; 107(1):57-60. PubMed ID: 6538200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of continuous-infusion cisplatin.
    Posner MR; Skarin AT; Clark J; Ervin TJ
    Cancer Treat Rep; 1986 Jul; 70(7):847-50. PubMed ID: 3013401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trials of WR-2721 and cis-platinum.
    Glover D; Glick JH; Weiler C; Yuhas J; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1781-4. PubMed ID: 6090371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Leroy A; Chang P; Klein M; Bachur NR; Wiernik PH
    Cancer; 1980 Oct; 46(8):1715-21. PubMed ID: 7191768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.
    Hayes DM; Cvitkovic E; Golbey RB; Scheiner E; Helson L; Krakoff IH
    Cancer; 1977 Apr; 39(4):1372-81. PubMed ID: 856437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-arterial continuous infusion of cis-diamminedichloroplatinum in untreated head and neck cancer patients.
    Frustaci S; Barzan L; Tumolo S; Comoretto R; Quadu G; Galligioni E; Lorenzini M; Crivellari D; Caruso G; Piccinin G
    Cancer; 1986 Mar; 57(6):1118-23. PubMed ID: 3943035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract.
    Kantarjian H; Ajani JA; Karlin DA
    Oncology; 1985; 42(2):69-71. PubMed ID: 3921891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck.
    Wittes RE; Brescia F; Young CW; Magill GB; Golbey RB; Krakoff IH
    Oncology; 1975; 32(5-6):202-7. PubMed ID: 59332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.